Frances R. Balkwill

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

105h-index66.0kcitations740works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(138), Immune cells in cancer(117), Cytokine Signaling Pathways and Interactions(97), Immunotherapy and Immune Responses(91), Monoclonal and Polyclonal Antibodies Research(72)

Publications740 total

Figure 5 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Figure 2 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Figure 6 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Figure 4 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Figure 3 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Figure 1 from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
2025Open Access
Perceptions of STEM Barriers in Adolescence: Examining Math Interest, Science Interest, and STEM Identity at Informal Science Learning Sites
Youth & Society·2025
Biomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion
Nature Communications·2025· 1 citedOpen Access
Supplemental Figure 14 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplementary Table 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplemental Figure 6 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplementary Table 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplementary Table 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Collaborating With Schools for Public Health Research in England: Lessons Learned for Successful Partnerships
Environmental Health Insights·2025Open Access
Supplemental Figure 13 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Data from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplemental Figure 12 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
Supplemental Figure 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
2025Open Access
page 1 of 37Next →

Frequent Co-authors

Hagen Kulbe(8), Alberto Mantovani(7), Thorsten Hagemann(7), Kellie A. Charles(7), Julia L. Wilson(6), Iain A. McNeish(5), Frances Burke(5), Jermaine Coward(4), Gordon Stamp(4), Richard G. Thompson(4), Probir Chakravarty(4), James D. Brenton(3), Anil K. Sood(3), David D.L. Bowtell(3), Ningfeng Fiona Li(3), B Davies(3), Paola Allavena(2), Robert C. Bast(2), Jonathan S. Berek(2), George Coukos(2)